Skip to main content

Advertisement

Springer Nature Link
Log in

Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The use of 18F-fluoroethylcholine (FEC) PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma (RCC) was prospectively analysed.

Methods

Preliminary results of two patients with metastatic RCC who underwent tumour nephrectomy as well as FEC PET/CT before and 10 weeks after two cycles of tyrosine kinase inhibitor therapy are presented.

Results

All in all, 18 tumour lesions were detected by baseline PET/CT, of which 10 (56%) were positive in FEC PET and 17 (94%) visible on contrast-enhanced computed tomography (ceCT). Mainly, small lung metastases resulted in the lower detection rate of FEC PET compared with ceCT. In follow-up PET/CT of the first case, progressive disease (PD) occurred with increase in tumour diameters of all metastases but non-uniform metabolic response. In the second case, partial response (PR) was achieved with concordant results of PET and CT. These results were confirmed by further CT in the course of disease.

Conclusions

In this small sample more than half of the RCC metastases were evident in baseline FEC PET. Monitoring therapy, FEC PET showed heterogeneous results in the first case with PD and was consistent with ceCT in the second one displaying PR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 2009;103:615–9.

    Article  PubMed  Google Scholar 

  2. Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun. 2009;30:519–24.

    Article  CAS  PubMed  Google Scholar 

  3. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511–20.

    Article  PubMed  Google Scholar 

  4. Martínez de Llano SR, Delgado-Bolton RC, Jiménez-Vicioso A, Pérez-Castejón MJ, Carreras Delgado JL, Ramos E, et al. Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma. Rev Esp Med Nucl. 2007;26:19–29.

    Article  PubMed  Google Scholar 

  5. Ide M, Suzuki Y, Kameyama G, Takahashi W, Koide S, Hinohara S, et al. The detection of renal cell carcinoma with adrenal and para-aortic lymph node metastases by FDG-PET. Eur J Nucl Med Mol Imaging. 2005;32:1246.

    Article  PubMed  Google Scholar 

  6. Snow D, Cohen D, Chapman WC, Grubb RL 3rd. Positron emission tomography enhancing tumor thrombus in patient with renal cell carcinoma. Urology. 2009;73:270–1.

    Article  PubMed  Google Scholar 

  7. Thambugala GM, Mohamed A, O’Neill GF, Fulham MJ. Sarcomatoid renal cell carcinoma: rapid dissemination detected on FDG PET-CT. Australas Radiol. 2006;50:604–6.

    Article  CAS  PubMed  Google Scholar 

  8. Kotzerke J, Linné C, Meinhardt M, Steinbach J, Wirth M, Baretton G, et al. [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:884–8.

    Article  CAS  PubMed  Google Scholar 

  9. Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:422–7.

    Article  PubMed  Google Scholar 

  10. Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31:788–9.

    Article  PubMed  Google Scholar 

  11. Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, et al. Initial experience with the radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid (anti-[(18)F]FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11:434–8.

    Article  PubMed  Google Scholar 

  12. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304–10.

    Article  CAS  PubMed  Google Scholar 

  13. Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96:540–6.

    Article  PubMed  Google Scholar 

  14. Bhargava P, Hanif M, Nash C. Whole-body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma. Clin Nucl Med. 2008;33:894–5.

    Article  PubMed  Google Scholar 

  15. Chang CH, Shiau YC, Shen YY, Kao A, Lin CC, Lee CC. Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography—a preliminary report. Urol Int. 2003;71:306–9.

    Article  CAS  PubMed  Google Scholar 

  16. Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009;24:137–44.

    Article  CAS  PubMed  Google Scholar 

  17. Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, et al. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009;95:382–4.

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

There have been no conflicts of interest and ethical adherence. Authors contributing to this study have not received any funding.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Hospital of the JW Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    Marcus Middendorp, Bruno Sauter & Frank Grünwald

  2. Department of Oncology, Hospital of the JW Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    Luise Maute

  3. Department of Radiology, Hospital of the JW Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    Thomas J. Vogl

Authors
  1. Marcus Middendorp
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Luise Maute
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Bruno Sauter
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Thomas J. Vogl
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Frank Grünwald
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Marcus Middendorp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Middendorp, M., Maute, L., Sauter, B. et al. Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med 24, 441–446 (2010). https://doi.org/10.1007/s12149-010-0375-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-010-0375-9

Keywords